


HEALTHCARE

## **The Specialty Pharma Market Outlook**

Key players, new company growth models and emerging opportunities

By Revati Nehru

 [Table of Contents](#)

## **Revati Nehru**

Revati Nehru has 3 years experience in healthcare marketing and market analysis in the cancer and cardiovascular market. During this time she has worked for multinational pharmaceutical companies and independent research houses. She is currently employed as a healthcare market analyst.

Copyright © 2006 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

# Table of Contents

## The Specialty Pharma Market Outlook

<b>Executive Summary</b>	<b>10</b>
The specialty pharmaceutical sector	10
Specialty Markets	11
Case studies of Specialty Players	12
Future outlook for the specialty pharmaceuticals sector	13
<b>Chapter 1           The specialty pharmaceuticals sector</b>	<b>16</b>
Summary	16
Background	17
Scope	18
The specialty pharma opportunity	20
Evolution of the specialty pharmaceuticals sector	20
Value chain specialization and types of specialty strategies	22
Market differentiation	23
Technological differentiation	25
Product and portfolio strategies	26
Classification of specialty pharmaceutical companies	29
Branded generics companies	29
Niche indications and orphan drugs	30
Drug delivery and reformulation companies	31
Deal-flow in the specialty pharma sector	32
Financial performance in the specialty pharma sector	38
Variation in operating profitability and revenues across the sector	38
<b>Chapter 2           Specialty therapeutic markets</b>	<b>44</b>
Summary	44

<b>Introduction</b>	<b>45</b>
<b>Analysis of key markets in the specialty pharma sector</b>	<b>46</b>
<b>Types of specialty pharmaceutical companies and market strategies</b>	<b>47</b>
Dermatology	49
Market overview	49
Key players in the specialty dermatology market	54
Ophthalmology	56
Market overview	56
Key players in the specialty ophthalmology market	61
Women's health	63
Market overview	63
Key players in the specialty women's health market	68
Urology	70
Market overview	70
Key players in the specialty urology market	73
CNS disorders	75
Market overview	75
Key players in the specialty CNS disorders market	81
Cardiovascular diseases	84
Market overview	84
Key players in the specialty cardiovascular market	88
<b>Future markets</b>	<b>90</b>

## **Chapter 3                    Case studies of specialty players                    94**

<b>Summary</b>	<b>94</b>
<b>Introduction</b>	<b>95</b>
<b>Types of specialty pharmaceutical companies</b>	<b>95</b>
<b>Company case studies</b>	<b>97</b>
Corporate strategy	97
Current dynamics of specialty pharmaceutical companies	99
<b>Allergan</b>	<b>102</b>
Summary	102
Competitive strategy	102
Portfolio analysis	105
Deal flow	108
Major franchise developments	111
R&D pipeline	113
<b>Elan</b>	<b>114</b>
Summary	114
Competitive strategy	115
Portfolio analysis	118
Deal flow	122
Major franchise developments	125
R&D pipeline	126

<b>Biovail</b>	<b>128</b>
Summary	128
Competitive strategy	129
Portfolio analysis	131
Deal flow	135
Major franchise developments	139
R&D pipeline	140
<b>Watson</b>	<b>142</b>
Summary	142
Competitive strategy	143
Portfolio analysis	145
Generics portfolio	146
Branded portfolio	148
Deal flow	150
Major franchise developments	152
R&D pipeline	155
<b>Shire</b>	<b>156</b>
Summary	156
Competitive strategy	157
Product portfolio analysis	159
Deal flow	163
Major franchise developments	166
R&D pipeline	167
<b>K-V</b>	<b>169</b>
Summary	169
Competitive strategy	169
Portfolio analysis	171
Deal flow	174
Major franchise developments	176
R&D pipeline	177

## **Chapter 4      Future outlook for the specialty pharmaceuticals sector      180**

<b>Summary</b>	<b>180</b>
<b>Introduction</b>	<b>181</b>
<b>Major competitive pressures on the specialty pharmaceuticals sector</b>	<b>181</b>
<b>Future specialty pharmaceutical growth models</b>	<b>184</b>
Drug delivery/reformulation based specialty companies	185
Generics manufacturing based specialty companies	186
Branded/niche marketing based specialty companies	186

<b>Chapter 5</b>	<b>Appendix</b>	<b>188</b>
Primary research methodology		188
Index		192
Glossary		197

# List of Figures

Figure 1.1:	Value chains of major components of the specialty pharmaceutical sector	19
Figure 1.2:	Relationships between Big Pharma and Specialty Pharma	21
Figure 1.3:	Specialty Pharma - key opportunities along the value chain	22
Figure 1.4:	Market differentiation strategies	24
Figure 1.5:	Technological differentiation strategies	26
Figure 1.6:	Target selection in the specialty pharmaceuticals sector	28
Figure 1.7:	Long-term value-add strategies pursued by specialty generics companies	30
Figure 1.8:	Deal flow by company type among a sample of 70 specialty pharmaceutical companies	33
Figure 1.9:	Evolution of Big Pharma as a source of product acquisition	34
Figure 1.10:	Synopsis of strategic fit in product/R&D acquisition	36
Figure 1.11:	Deal-flow by company type among a sample of 70 specialty pharmaceutical companies	37
Figure 1.12:	Comparisons of operating performance across the specialty pharmaceuticals sector	39
Figure 1.13:	Comparisons of EPS across the specialty pharmaceuticals sector	41
Figure 2.14:	Market matrix for specialty pharmaceutical company types across key indications	47
Figure 2.15:	Comparative attractiveness of key sub-indications in the dermatology market	50
Figure 2.16:	Estimated sales in the specialty dermatology market by sub-indication, 2005	51
Figure 2.17:	Comparative attractiveness of key sub-indications in the ophthalmology market	57
Figure 2.18:	Estimated sales in the specialty ophthalmology market by sub-indication, 2005	58
Figure 2.19:	Comparative attractiveness of key sub-indications in the women's health market	64
Figure 2.20:	Estimated sales in specialty women's health by sub-indications, 2005	65
Figure 2.21:	Comparative attractiveness of key sub-indications in the urology market	70
Figure 2.22:	Estimated sales in the specialty urology market by sub-indication, 2005	71
Figure 2.23:	Estimated sales in the specialty CNS market by sub-indication, 2005	76
Figure 2.24:	Comparative attractiveness of key sub-indications in the CNS disorders market	77
Figure 2.25:	Comparative attractiveness of key sub-indications in the cardiovascular disorders market, 2005	85
Figure 2.26:	Estimated sales in the cardiovascular market by sub-indication, 2005	86
Figure 2.27:	Future market development in the specialty pharmaceutical sector	91
Figure 3.28:	Areas of focus of specialty pharmaceutical companies	96
Figure 3.29:	Specialty pharmaceuticals corporate deals, 2000-2006	98
Figure 3.30:	Core competencies of specialty pharmaceutical companies	100
Figure 3.31:	Allergan: SWOT analysis	103
Figure 3.32:	Allergan's commercial agreements flow, 2000-2005	111
Figure 3.33:	Elan: SWOT analysis	116
Figure 3.34:	Biovail: SWOT analysis	129
Figure 3.35:	Biovail's commercial agreements, 2000-2005	139
Figure 3.36:	Watson: SWOT analysis	143
Figure 3.37:	Watson's commercial agreements, 2000-2006	152
Figure 3.38:	Shire: SWOT analysis	158
Figure 3.39:	Shire's commercial agreements, 2000-2006	166
Figure 3.40:	KV: SWOT analysis	170
Figure 3.41:	KV's commercial agreements, 2000-2006	177
Figure 4.42:	Forecast future trends in the specialty pharmaceutical sector	184
Figure 4.43:	Forecast changes in value chain distribution, 2011-2016	185

# List of Tables

Table 2.1:	Key specialty indications and market sizes, 2005	46
Table 2.2:	Key players in the specialty dermatology market, 2005	54
Table 2.3:	Key players in the specialty ophthalmology market, 2005	61
Table 2.4:	Key players in the specialty women's health market, 2005	68
Table 2.5:	Key players in the specialty urology market, 2005	73
Table 2.6:	Key players in the specialty CNS market, 2005	81
Table 2.7:	Key players in the cardiovascular market, 2005	88
Table 3.8:	Breakdown of segment revenues	105
Table 3.9:	Allergan's commercial agreements, 2000-2005	109
Table 3.10:	Allergan's R&D pipeline, 2006	113
Table 3.11:	Elan's breakdown of segment revenues	118
Table 3.12:	Elan's product portfolio	119
Table 3.13:	Elan's corporate agreements, 2000-2006	122
Table 3.14:	Elan's corporate agreements, 2000-2006 continued	123
Table 3.15:	Elan's recovery plan agreements, August 2002-February 2004	124
Table 3.16:	Elan's commercial agreements, 2000-2005	125
Table 3.17:	Elan's R&D pipeline, 2006	126
Table 3.18:	Biovail's product portfolio	132
Table 3.19:	Biovail corporate agreements, 2000-2005	136
Table 3.20:	Biovail's R&D pipeline	140
Table 3.21:	Breakdown of segment revenues	145
Table 3.22:	Watson's branded product portfolio	148
Table 3.23:	Watson's corporate agreements, 2000-2006	151
Table 3.24:	Watson's R&D pipeline	155
Table 3.25:	Shire's product portfolio	160
Table 3.26:	Shire corporate agreements, 2000-2006	164
Table 3.27:	Shire's R&D pipeline	167
Table 3.28:	Breakdown of segment revenues	172
Table 3.29:	KV corporate agreements, 2000-2006	175